Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study
Delayed treatment for first episodes of psychosis predicts worse outcomes. We hypothesised that delaying treatment makes all symptoms more refractory, with harm worsening first quickly, then more slowly. We also hypothesised that although delay impairs treatment response, worse symptoms hasten treat...
Gespeichert in:
| Veröffentlicht in: | The Lancet. Psychiatry 2020-07, Vol.7 (7), p.602-610 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 610 |
|---|---|
| container_issue | 7 |
| container_start_page | 602 |
| container_title | The Lancet. Psychiatry |
| container_volume | 7 |
| creator | Drake, Richard J Husain, Nusrat Marshall, Max Lewis, Shôn W Tomenson, Barbara Chaudhry, Imran B Everard, Linda Singh, Swaran Freemantle, Nick Fowler, David Jones, Peter B Amos, Tim Sharma, Vimal Green, Chloe D Fisher, Helen Murray, Robin M Wykes, Til Buchan, Iain Birchwood, Max |
| description | Delayed treatment for first episodes of psychosis predicts worse outcomes. We hypothesised that delaying treatment makes all symptoms more refractory, with harm worsening first quickly, then more slowly. We also hypothesised that although delay impairs treatment response, worse symptoms hasten treatment, which at presentation mitigates the detrimental effect of treatment delay on symptoms.
In this longitudinal analysis and modelling study, we included two longitudinal cohorts of patients with first-episode psychosis presenting to English early intervention services from defined catchments: NEDEN (recruiting 1003 patients aged 14–35 years from 14 services between Aug 1, 2005, and April 1, 2009) and Outlook (recruiting 399 patients aged 16–35 years from 11 services between April 1, 2006, and Feb 28, 2009). Patients were assessed at baseline, 6 months, and 12 months with the Positive and Negative Symptom Scale (PANSS), Calgary Depression Scale for Schizophrenia, Mania Rating Scale, Insight Scale, and Social and Occupational Functioning Assessment Scale. Regression was used to compare different models of the relationship between duration of untreated psychosis (DUP) and total symptoms at 6 months. Growth curve models of symptom subscales tested predictions arising from our hypotheses.
We included 948 patients from the NEDEN study and 332 patients from the Outlook study who completed baseline assessments and were prescribed dopamine antagonist antipsychotics. For both cohorts, the best-fitting models were logarithmic, describing a curvilinear relationship of DUP to symptom severity: longer DUP predicted reduced treatment response, but response worsened more slowly as DUP lengthened. Increasing DUP by ten times predicted reduced improvement in total symptoms (ie, PANSS total) by 7·339 (95% CI 5·762 to 8·916; p |
| doi_str_mv | 10.1016/S2215-0366(20)30147-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7606908</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2215036620301474</els_id><sourcerecordid>2415835263</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-74453f7acae8ce6cb016814cc10dfb1b10c9dd72cf932dce15773cc0743d6e083</originalsourceid><addsrcrecordid>eNqFUU2PFCEQJUbjbsb9CRqO66EVGhpmPGjMZv1INvGgnglTVM9iumEEepO--8OlZ8aJnrwAqXrvVfEeIc85e8UZV6-_ti3vGiaUum7ZS8G41I18RC5PZS0fn99KXZCrnH8wxriQrNPyKbkQbaeEYPqS_Lrte4RCY08dDnb2YUdLQltGDIdq71MuDe59jg7pPs9wH7PPNAaa53Ff4pipDY7mCN4ONE4F4oj5DbV0iGHny-R8qA1bj3khLuCxag3DMivX_vyMPOntkPHqdK_I9w-3324-NXdfPn6-eX_XgFS6NFrKTvTagsU1oIJttWLNJQBnrt_yLWewcU630G9E6wB5p7UAYFoKp5CtxYq8Perup-2IFRFKsoPZJz_aNJtovfm3E_y92cUHoxVTm4PA9UkgxZ8T5mJGn6F-xQaMUzat5N1adG01d0W6IxRSzDlhfx7DmVlCNIcQzZKQaZk5hGhk5b34e8cz609kFfDuCMDq1IPHZDJ4DIDOp5qkcdH_Z8Rv0DywSQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2415835263</pqid></control><display><type>article</type><title>Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Drake, Richard J ; Husain, Nusrat ; Marshall, Max ; Lewis, Shôn W ; Tomenson, Barbara ; Chaudhry, Imran B ; Everard, Linda ; Singh, Swaran ; Freemantle, Nick ; Fowler, David ; Jones, Peter B ; Amos, Tim ; Sharma, Vimal ; Green, Chloe D ; Fisher, Helen ; Murray, Robin M ; Wykes, Til ; Buchan, Iain ; Birchwood, Max</creator><creatorcontrib>Drake, Richard J ; Husain, Nusrat ; Marshall, Max ; Lewis, Shôn W ; Tomenson, Barbara ; Chaudhry, Imran B ; Everard, Linda ; Singh, Swaran ; Freemantle, Nick ; Fowler, David ; Jones, Peter B ; Amos, Tim ; Sharma, Vimal ; Green, Chloe D ; Fisher, Helen ; Murray, Robin M ; Wykes, Til ; Buchan, Iain ; Birchwood, Max</creatorcontrib><description>Delayed treatment for first episodes of psychosis predicts worse outcomes. We hypothesised that delaying treatment makes all symptoms more refractory, with harm worsening first quickly, then more slowly. We also hypothesised that although delay impairs treatment response, worse symptoms hasten treatment, which at presentation mitigates the detrimental effect of treatment delay on symptoms.
In this longitudinal analysis and modelling study, we included two longitudinal cohorts of patients with first-episode psychosis presenting to English early intervention services from defined catchments: NEDEN (recruiting 1003 patients aged 14–35 years from 14 services between Aug 1, 2005, and April 1, 2009) and Outlook (recruiting 399 patients aged 16–35 years from 11 services between April 1, 2006, and Feb 28, 2009). Patients were assessed at baseline, 6 months, and 12 months with the Positive and Negative Symptom Scale (PANSS), Calgary Depression Scale for Schizophrenia, Mania Rating Scale, Insight Scale, and Social and Occupational Functioning Assessment Scale. Regression was used to compare different models of the relationship between duration of untreated psychosis (DUP) and total symptoms at 6 months. Growth curve models of symptom subscales tested predictions arising from our hypotheses.
We included 948 patients from the NEDEN study and 332 patients from the Outlook study who completed baseline assessments and were prescribed dopamine antagonist antipsychotics. For both cohorts, the best-fitting models were logarithmic, describing a curvilinear relationship of DUP to symptom severity: longer DUP predicted reduced treatment response, but response worsened more slowly as DUP lengthened. Increasing DUP by ten times predicted reduced improvement in total symptoms (ie, PANSS total) by 7·339 (95% CI 5·762 to 8·916; p<0·0001) in NEDEN data and 3·846 (1·689 to 6·003; p=0·0005) in Outlook data. This was true of treatment response for all symptom types. Nevertheless, longer DUP was not associated with worse presentation for any symptoms except depression in NEDEN (coefficients 0·099 [95% CI 0·033 to 0·164]; p=0·0028 in NEDEN and 0·007 [−0·081 to 0·095]; p=0·88 in Outlook).
Long DUP was associated with reduced treatment response across subscales, consistent with a harmful process upstream of individual symptoms' mechanisms; response appeared to worsen quickly at first, then more slowly. These associations underscore the importance of rapid access to a comprehensive range of treatments, especially in the first weeks after psychosis onset.
UK Department of Health, National Institute of Health Research, and Medical Research Council.</description><identifier>ISSN: 2215-0366</identifier><identifier>EISSN: 2215-0374</identifier><identifier>DOI: 10.1016/S2215-0366(20)30147-4</identifier><identifier>PMID: 32563307</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Antipsychotic Agents - therapeutic use ; Dopamine Antagonists - therapeutic use ; Female ; Humans ; Logistic Models ; Longitudinal Studies ; Male ; Models, Psychological ; Psychiatric Status Rating Scales ; Psychotic Disorders - diagnosis ; Psychotic Disorders - drug therapy ; Psychotic Disorders - psychology ; Time Factors ; Time-to-Treatment ; Young Adult</subject><ispartof>The Lancet. Psychiatry, 2020-07, Vol.7 (7), p.602-610</ispartof><rights>2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4·0 license</rights><rights>Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4·0 license. Published by Elsevier Ltd.. All rights reserved.</rights><rights>2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4·0 license 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-74453f7acae8ce6cb016814cc10dfb1b10c9dd72cf932dce15773cc0743d6e083</citedby><cites>FETCH-LOGICAL-c467t-74453f7acae8ce6cb016814cc10dfb1b10c9dd72cf932dce15773cc0743d6e083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32563307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Drake, Richard J</creatorcontrib><creatorcontrib>Husain, Nusrat</creatorcontrib><creatorcontrib>Marshall, Max</creatorcontrib><creatorcontrib>Lewis, Shôn W</creatorcontrib><creatorcontrib>Tomenson, Barbara</creatorcontrib><creatorcontrib>Chaudhry, Imran B</creatorcontrib><creatorcontrib>Everard, Linda</creatorcontrib><creatorcontrib>Singh, Swaran</creatorcontrib><creatorcontrib>Freemantle, Nick</creatorcontrib><creatorcontrib>Fowler, David</creatorcontrib><creatorcontrib>Jones, Peter B</creatorcontrib><creatorcontrib>Amos, Tim</creatorcontrib><creatorcontrib>Sharma, Vimal</creatorcontrib><creatorcontrib>Green, Chloe D</creatorcontrib><creatorcontrib>Fisher, Helen</creatorcontrib><creatorcontrib>Murray, Robin M</creatorcontrib><creatorcontrib>Wykes, Til</creatorcontrib><creatorcontrib>Buchan, Iain</creatorcontrib><creatorcontrib>Birchwood, Max</creatorcontrib><title>Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study</title><title>The Lancet. Psychiatry</title><addtitle>Lancet Psychiatry</addtitle><description>Delayed treatment for first episodes of psychosis predicts worse outcomes. We hypothesised that delaying treatment makes all symptoms more refractory, with harm worsening first quickly, then more slowly. We also hypothesised that although delay impairs treatment response, worse symptoms hasten treatment, which at presentation mitigates the detrimental effect of treatment delay on symptoms.
In this longitudinal analysis and modelling study, we included two longitudinal cohorts of patients with first-episode psychosis presenting to English early intervention services from defined catchments: NEDEN (recruiting 1003 patients aged 14–35 years from 14 services between Aug 1, 2005, and April 1, 2009) and Outlook (recruiting 399 patients aged 16–35 years from 11 services between April 1, 2006, and Feb 28, 2009). Patients were assessed at baseline, 6 months, and 12 months with the Positive and Negative Symptom Scale (PANSS), Calgary Depression Scale for Schizophrenia, Mania Rating Scale, Insight Scale, and Social and Occupational Functioning Assessment Scale. Regression was used to compare different models of the relationship between duration of untreated psychosis (DUP) and total symptoms at 6 months. Growth curve models of symptom subscales tested predictions arising from our hypotheses.
We included 948 patients from the NEDEN study and 332 patients from the Outlook study who completed baseline assessments and were prescribed dopamine antagonist antipsychotics. For both cohorts, the best-fitting models were logarithmic, describing a curvilinear relationship of DUP to symptom severity: longer DUP predicted reduced treatment response, but response worsened more slowly as DUP lengthened. Increasing DUP by ten times predicted reduced improvement in total symptoms (ie, PANSS total) by 7·339 (95% CI 5·762 to 8·916; p<0·0001) in NEDEN data and 3·846 (1·689 to 6·003; p=0·0005) in Outlook data. This was true of treatment response for all symptom types. Nevertheless, longer DUP was not associated with worse presentation for any symptoms except depression in NEDEN (coefficients 0·099 [95% CI 0·033 to 0·164]; p=0·0028 in NEDEN and 0·007 [−0·081 to 0·095]; p=0·88 in Outlook).
Long DUP was associated with reduced treatment response across subscales, consistent with a harmful process upstream of individual symptoms' mechanisms; response appeared to worsen quickly at first, then more slowly. These associations underscore the importance of rapid access to a comprehensive range of treatments, especially in the first weeks after psychosis onset.
UK Department of Health, National Institute of Health Research, and Medical Research Council.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Dopamine Antagonists - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Models, Psychological</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychotic Disorders - diagnosis</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Psychotic Disorders - psychology</subject><subject>Time Factors</subject><subject>Time-to-Treatment</subject><subject>Young Adult</subject><issn>2215-0366</issn><issn>2215-0374</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUU2PFCEQJUbjbsb9CRqO66EVGhpmPGjMZv1INvGgnglTVM9iumEEepO--8OlZ8aJnrwAqXrvVfEeIc85e8UZV6-_ti3vGiaUum7ZS8G41I18RC5PZS0fn99KXZCrnH8wxriQrNPyKbkQbaeEYPqS_Lrte4RCY08dDnb2YUdLQltGDIdq71MuDe59jg7pPs9wH7PPNAaa53Ff4pipDY7mCN4ONE4F4oj5DbV0iGHny-R8qA1bj3khLuCxag3DMivX_vyMPOntkPHqdK_I9w-3324-NXdfPn6-eX_XgFS6NFrKTvTagsU1oIJttWLNJQBnrt_yLWewcU630G9E6wB5p7UAYFoKp5CtxYq8Perup-2IFRFKsoPZJz_aNJtovfm3E_y92cUHoxVTm4PA9UkgxZ8T5mJGn6F-xQaMUzat5N1adG01d0W6IxRSzDlhfx7DmVlCNIcQzZKQaZk5hGhk5b34e8cz609kFfDuCMDq1IPHZDJ4DIDOp5qkcdH_Z8Rv0DywSQ</recordid><startdate>202007</startdate><enddate>202007</enddate><creator>Drake, Richard J</creator><creator>Husain, Nusrat</creator><creator>Marshall, Max</creator><creator>Lewis, Shôn W</creator><creator>Tomenson, Barbara</creator><creator>Chaudhry, Imran B</creator><creator>Everard, Linda</creator><creator>Singh, Swaran</creator><creator>Freemantle, Nick</creator><creator>Fowler, David</creator><creator>Jones, Peter B</creator><creator>Amos, Tim</creator><creator>Sharma, Vimal</creator><creator>Green, Chloe D</creator><creator>Fisher, Helen</creator><creator>Murray, Robin M</creator><creator>Wykes, Til</creator><creator>Buchan, Iain</creator><creator>Birchwood, Max</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202007</creationdate><title>Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study</title><author>Drake, Richard J ; Husain, Nusrat ; Marshall, Max ; Lewis, Shôn W ; Tomenson, Barbara ; Chaudhry, Imran B ; Everard, Linda ; Singh, Swaran ; Freemantle, Nick ; Fowler, David ; Jones, Peter B ; Amos, Tim ; Sharma, Vimal ; Green, Chloe D ; Fisher, Helen ; Murray, Robin M ; Wykes, Til ; Buchan, Iain ; Birchwood, Max</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-74453f7acae8ce6cb016814cc10dfb1b10c9dd72cf932dce15773cc0743d6e083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Dopamine Antagonists - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Models, Psychological</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychotic Disorders - diagnosis</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Psychotic Disorders - psychology</topic><topic>Time Factors</topic><topic>Time-to-Treatment</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Drake, Richard J</creatorcontrib><creatorcontrib>Husain, Nusrat</creatorcontrib><creatorcontrib>Marshall, Max</creatorcontrib><creatorcontrib>Lewis, Shôn W</creatorcontrib><creatorcontrib>Tomenson, Barbara</creatorcontrib><creatorcontrib>Chaudhry, Imran B</creatorcontrib><creatorcontrib>Everard, Linda</creatorcontrib><creatorcontrib>Singh, Swaran</creatorcontrib><creatorcontrib>Freemantle, Nick</creatorcontrib><creatorcontrib>Fowler, David</creatorcontrib><creatorcontrib>Jones, Peter B</creatorcontrib><creatorcontrib>Amos, Tim</creatorcontrib><creatorcontrib>Sharma, Vimal</creatorcontrib><creatorcontrib>Green, Chloe D</creatorcontrib><creatorcontrib>Fisher, Helen</creatorcontrib><creatorcontrib>Murray, Robin M</creatorcontrib><creatorcontrib>Wykes, Til</creatorcontrib><creatorcontrib>Buchan, Iain</creatorcontrib><creatorcontrib>Birchwood, Max</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Lancet. Psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Drake, Richard J</au><au>Husain, Nusrat</au><au>Marshall, Max</au><au>Lewis, Shôn W</au><au>Tomenson, Barbara</au><au>Chaudhry, Imran B</au><au>Everard, Linda</au><au>Singh, Swaran</au><au>Freemantle, Nick</au><au>Fowler, David</au><au>Jones, Peter B</au><au>Amos, Tim</au><au>Sharma, Vimal</au><au>Green, Chloe D</au><au>Fisher, Helen</au><au>Murray, Robin M</au><au>Wykes, Til</au><au>Buchan, Iain</au><au>Birchwood, Max</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study</atitle><jtitle>The Lancet. Psychiatry</jtitle><addtitle>Lancet Psychiatry</addtitle><date>2020-07</date><risdate>2020</risdate><volume>7</volume><issue>7</issue><spage>602</spage><epage>610</epage><pages>602-610</pages><issn>2215-0366</issn><eissn>2215-0374</eissn><abstract>Delayed treatment for first episodes of psychosis predicts worse outcomes. We hypothesised that delaying treatment makes all symptoms more refractory, with harm worsening first quickly, then more slowly. We also hypothesised that although delay impairs treatment response, worse symptoms hasten treatment, which at presentation mitigates the detrimental effect of treatment delay on symptoms.
In this longitudinal analysis and modelling study, we included two longitudinal cohorts of patients with first-episode psychosis presenting to English early intervention services from defined catchments: NEDEN (recruiting 1003 patients aged 14–35 years from 14 services between Aug 1, 2005, and April 1, 2009) and Outlook (recruiting 399 patients aged 16–35 years from 11 services between April 1, 2006, and Feb 28, 2009). Patients were assessed at baseline, 6 months, and 12 months with the Positive and Negative Symptom Scale (PANSS), Calgary Depression Scale for Schizophrenia, Mania Rating Scale, Insight Scale, and Social and Occupational Functioning Assessment Scale. Regression was used to compare different models of the relationship between duration of untreated psychosis (DUP) and total symptoms at 6 months. Growth curve models of symptom subscales tested predictions arising from our hypotheses.
We included 948 patients from the NEDEN study and 332 patients from the Outlook study who completed baseline assessments and were prescribed dopamine antagonist antipsychotics. For both cohorts, the best-fitting models were logarithmic, describing a curvilinear relationship of DUP to symptom severity: longer DUP predicted reduced treatment response, but response worsened more slowly as DUP lengthened. Increasing DUP by ten times predicted reduced improvement in total symptoms (ie, PANSS total) by 7·339 (95% CI 5·762 to 8·916; p<0·0001) in NEDEN data and 3·846 (1·689 to 6·003; p=0·0005) in Outlook data. This was true of treatment response for all symptom types. Nevertheless, longer DUP was not associated with worse presentation for any symptoms except depression in NEDEN (coefficients 0·099 [95% CI 0·033 to 0·164]; p=0·0028 in NEDEN and 0·007 [−0·081 to 0·095]; p=0·88 in Outlook).
Long DUP was associated with reduced treatment response across subscales, consistent with a harmful process upstream of individual symptoms' mechanisms; response appeared to worsen quickly at first, then more slowly. These associations underscore the importance of rapid access to a comprehensive range of treatments, especially in the first weeks after psychosis onset.
UK Department of Health, National Institute of Health Research, and Medical Research Council.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32563307</pmid><doi>10.1016/S2215-0366(20)30147-4</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2215-0366 |
| ispartof | The Lancet. Psychiatry, 2020-07, Vol.7 (7), p.602-610 |
| issn | 2215-0366 2215-0374 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7606908 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Antipsychotic Agents - therapeutic use Dopamine Antagonists - therapeutic use Female Humans Logistic Models Longitudinal Studies Male Models, Psychological Psychiatric Status Rating Scales Psychotic Disorders - diagnosis Psychotic Disorders - drug therapy Psychotic Disorders - psychology Time Factors Time-to-Treatment Young Adult |
| title | Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T06%3A41%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20delaying%20treatment%20of%20first-episode%20psychosis%20on%20symptoms%20and%20social%20outcomes:%20a%20longitudinal%20analysis%20and%20modelling%20study&rft.jtitle=The%20Lancet.%20Psychiatry&rft.au=Drake,%20Richard%20J&rft.date=2020-07&rft.volume=7&rft.issue=7&rft.spage=602&rft.epage=610&rft.pages=602-610&rft.issn=2215-0366&rft.eissn=2215-0374&rft_id=info:doi/10.1016/S2215-0366(20)30147-4&rft_dat=%3Cproquest_pubme%3E2415835263%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2415835263&rft_id=info:pmid/32563307&rft_els_id=S2215036620301474&rfr_iscdi=true |